<DOC>
	<DOC>NCT00851734</DOC>
	<brief_summary>This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.</brief_summary>
	<brief_title>A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>No systemic disease as determined by a physical examination, clinical laboratory evaluation, and an ECG Schirmer's I Test â‰¥ 10mm/5 minutes with anesthesia Corrected Snellen acuity of 20/40 or better in both eyes Subjects diagnosed with any ocular disease other than refraction error Subjects with intraocular pressure &gt;21 mmHg Use of a contact lens within 7 days prior to administration of the first dose Subjects with history of ocular surgery Subjects with a history of laser refractive surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>